BioN­Tech ex­pands ADC deal with Du­al­i­ty­Bio; Gra­cell and IO Biotech get pri­vate place­ments from a slew of in­vestors

BioN­Tech is forg­ing a big­ger al­liance with its an­ti­body-drug con­ju­gate part­ner Du­al­i­ty­Bio, adding an­oth­er ADC to their bil­lion-dol­lar union.

Du­al­i­ty­Bio an­nounced the strate­gic ex­pan­sion on Mon­day, say­ing that the Shang­hai biotech will re­ceive undis­closed up­front pay­ments, along with ad­di­tion­al mile­stones and roy­al­ties from BioN­Tech for DB-1305, which is be­ing test­ed in a Phase I/II sol­id tu­mor tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER